Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. Planned enrollment will rise from 12 to 36 patients, based on continued safety, tolerability and early clinical activity, to better assess ORR, PFS and biomarkers with pembrolizumab and chemotherapy. Updates are expected through 2026-2027.
How this was made
The 30-second read
Why it matters
Expanding Phase 1b enrollment increases statistical/clinical interpretability of ORR, PFS, and translational biomarker analyses, which can shift perceived probability of success for the paxalisib combination strategy in TNBC.
Market read
A direct, company-specific clinical development update that improves the dataset size for a lead asset’s TNBC combination regimen.
What to watch
Abstract withdrawal for IP reasons may reduce near-term conference-driven visibility, potentially tempering short-term sentiment despite the enrollment increase.
Background
Kazia’s paxalisib is an investigational brain-penetrant PI3K/Akt/mTOR pathway inhibitor being tested across multiple oncology indications, including advanced breast cancer.
Ticker impact
Kazia plans to expand its Phase 1b paxalisib + pembrolizumab/chemotherapy trial in advanced TNBC, raising enrollment from 12 to 36.
Near-term upside bias as investors price in a larger, more informative readout window; volatility likely remains high given early-stage nature.
The company is directly advancing a lead asset with a clear trial design change and expects more clinical/translational updates through 2026-2027.
Market effects
Supports continued investor interest in PI3K/mTOR pathway inhibitors and combination immunotherapy strategies in TNBC.
Limited direct regional impact; primarily a US-listed small/mid-cap biotech catalyst.
Broad relevance for global TNBC drug development and PI3K/mTOR + checkpoint inhibitor combination research.
Counterpoint
Phase 1b remains early-stage and open-label; larger enrollment may not translate into durable efficacy signals.
Key entities
- companyKazia Therapeutics
Expanding Phase 1b paxalisib combination trial in advanced triple-negative breast cancer; enrollment increases from 12 to 36.
- drugpaxalisib
Investigational PI3K/Akt/mTOR inhibitor being evaluated with pembrolizumab and chemotherapy in TNBC.
- drugpembrolizumab
Checkpoint inhibitor used in combination with paxalisib and chemotherapy in the expanded trial.
